🇺🇸

US SEC Filing Intelligence

· daily

Federal IT & Cybersecurity Contracts — April 07, 2026

Peraton Enterprise Solutions LLC secured the sole contract in this digest, a $346,769,435 obligated delivery order from GSA's FEDSIM office for computer systems design services, representing 100% civilian exposure with 0/1 defense-related awards. This full and open competition win under a cost-plus award fee structure signals strong positioning in GSA civilian IT support, with potential upside to $562,995,039 including options through 2027. The highest-conviction bullish signal is the low financial risk and multi-year revenue visibility for Peraton, estimating $87M-$113M annually. A key watch item is total outlay progress from the current $0, as execution dependency and high subcontracting ($357M across 369 subs) could delay revenue realization.

1 total filings
· daily

NASA & Space Contracts Intelligence — April 07, 2026

NASA awarded Lockheed Martin Corp a $69,721,101 firm fixed price contract for the Tipping Point Cryogenic Demonstration Mission, representing the sole obligation in this NASA & Space Contracts Intelligence stream with a 0/1 defense-related split, fully civilian-focused. The contract, managed by NASA Marshall Space Flight Center under full and open competition (NAICS 541715, PSC AR13), underscores Lockheed's space R&D expertise with $62,721,101 already outlayed and 157 subawards totaling $27,812,346. The highest-conviction signal is bullish for Lockheed Martin, signaling steady revenue through 2026 amid space technology priorities. A key watch item is the remaining $7M outlay and performance completion by 2026-04-03, coupled with high pricing risk under firm fixed price terms.

1 total filings
· daily

All HHS Contracts — April 07, 2026

HHS obligated $144,045,451 across 1 contract during the April 07, 2026 period, with 0% defense-related and 100% civilian allocation to NIH construction projects. The dominant theme is institutional building conversion at NIH's Poolesville facility, led by a single high-materiality award to Hensel Phelps Construction Co. The highest-conviction bullish signal is multi-year revenue visibility from the fully funded $144M firm fixed price delivery order, with $30.6M already outlayed signaling early execution. Key watch item is outlay progress beyond $30.6M and performance toward the December 20, 2028 end date (potential February 9, 2029), amid high pricing risk from the firm fixed price structure.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — April 07, 2026

Four mega contracts totaling $922,974,283 in obligations, all awarded to civilian agencies (0/4 defense-related), highlight robust federal IT, telecom, and construction spending across GSA, Treasury/IRS, DOT/FAA, and HHS/NIH. Peraton Enterprise Solutions LLC's $346.8M GSA IT delivery order and Rohde & Schwarz USA Inc.'s $167.6M FAA voice communication systems award represent the highest-conviction bullish signals due to their top materiality scores (8/10) and multi-year revenue potential up to $563M and $250M respectively including options. Verizon Business Network Services LLC's $264.6M IRS telecom transition and Hensel Phelps Construction Co's $144M NIH building conversion add diversified civilian exposure with partial outlays already at $209.4M and $30.6M. Key risk: zero outlays on Peraton and Rohde & Schwarz contracts signal execution dependency ahead of revenue recognition.

4 total filings
· daily

High-Value Federal Grants ($5M+) — April 07, 2026

These five high-value civilian federal contracts total $992,695,384 in obligations, with 0/5 defense-related, highlighting robust spending across GSA, Treasury/IRS, DOT/FAA, HHS/NIH, and NASA. Dominant themes include IT systems design, telecommunications transitions, voice communication infrastructure, building construction, and space R&D, all awarded via full and open competition to non-small businesses. Highest-conviction bullish signal is Peraton Enterprise Solutions LLC's $346.8M GSA delivery order for computer systems design, offering low-risk cost-plus structure and up to $563M potential. Verizon Business Network Services LLC's $264.6M IRS telecom order shows strong execution with $209M outlayed. Key risk is execution dependency, as three contracts (Peraton, Rohde & Schwarz USA Inc., Hensel Phelps) have minimal or zero outlays despite large obligations, alongside high firm-fixed-price risks in Rohde ($167.6M FAA), Hensel Phelps ($144M NIH), and Lockheed Martin ($69.7M NASA).

5 total filings
· daily

General Federal Contracts — April 07, 2026

These five civilian contracts totaling $992,695,384 in obligations represent strong bullish signals for institutional investors eyeing non-defense government services exposure, with zero defense-related awards across GSA, Treasury/IRS, DOT/FAA, HHS/NIH, and NASA. Dominant themes include multi-year IT systems design, telecommunications transitions, and infrastructure construction, led by Peraton Enterprise Solutions LLC's highest-materiality $346.8M GSA award for computer systems design services. Highest-conviction signal is Peraton's cost-plus structure reducing execution risk over a 4-5 year horizon with up to $563M potential. Key risk is zero outlays to date on the two largest contracts (Peraton and Rohde & Schwarz), signaling future revenue dependency on execution milestones.

5 total filings
· daily

All NASA Contracts — April 07, 2026

NASA awarded a single $69,721,101 firm fixed price contract to Lockheed Martin Corp for the Tipping Point Cryogenic Demonstration Mission, representing 100% civilian obligations with zero defense-related activity during the April 07, 2026 period. This full and open competition win under NAICS 541715 for space R&D services aligns with Lockheed Martin's space expertise, with $62,721,101 already outlayed and 157 subawards totaling $27,812,346. The highest-conviction bullish signal is validation of Lockheed Martin's competitive position in NASA space R&D, contributing an estimated $14.9M annual revenue through 2026-04-03. A key watch item is the remaining $7M outlays and performance completion by 2026-04-03, amid high contract pricing risk due to firm fixed price terms.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 07, 2026

Across the 10 filings in the USA S&P 500 Technology intelligence stream, governance and proxy-related disclosures dominate (5/10 filings), highlighting heightened shareholder activism and board defenses amid sector pressures. Period-over-period trends are sparse but stark in Aditxt's acquisition of Ignite Proteomics, where net losses widened 154% YoY to $5.7M, revenues plunged 40% to $43.5k, assets dropped 76% to $257k, and liabilities tripled to $7.1M, raising integration risks. Leadership transitions show stability with PSQ's seamless CFO handover and QumulusAI's stabilized exec team post-multiple changes, contrasting Aditxt's troubled M&A. Mixed sentiments prevail (e.g., Genco's proxy battle rejecting $23.50/share takeover), with neutral routine updates in CDCC, FHLB bonds, and bank filings; overall, low sector-wide growth signals but opportunities in IPO prep (QumulusAI) and financial structure shifts (Chemung). Critical implications include monitoring May 2026 AGMs for voting outcomes and takeover escalations, as capital allocation remains defensive with no dividend/buyback accelerations noted. Portfolio-level pattern: 40% of filings flag governance catalysts, potentially driving volatility in tech-adjacent names.

3 high priority 7 medium 10 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 07, 2026

Across 14 filings from NASDAQ-100 related entities, dominant themes include the onset of 2026 proxy season with multiple annual meetings clustered in May (Camden May 8, PayPal May 19, First Community May 20), highlighting governance votes, exec comp approvals, and director elections amid post-merger adjustments and proxy contests. Period-over-period trends show stark contrasts: PayPal's robust 2025 growth (TPV +7% YoY to $1.79T, revenues +4% to $33.2B, non-GAAP EPS +14% to $5.31, $6B buybacks) versus Aditxt's acquired Ignite Proteomics' deteriorating metrics (net loss widened to $5.7M from $2.2M YoY, revenues -40% to $43.5K, assets -76% to $257K, liabilities +3x to $7.1M with going concern doubts). Capital allocation leans shareholder-friendly in PayPal ($6.4B cash flow matched by repurchases), while M&A reveals risks (Aditxt impairment) and defenses (Genco rejecting $23.50/share bid as undervalued). Mixed sentiments prevail in performance disclosures (PayPal branded checkout misses, CEO transition; CCC exec departures), with neutral routine updates elsewhere. Portfolio-level patterns signal monitoring proxy battles and May catalysts for volatility, favoring strong performers like PayPal amid sector governance focus.

4 high priority 10 medium 14 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 07, 2026

The 50 filings from the USA S&P 500 Financials stream reveal a dominant proxy season theme with 20+ DEF 14A/DEFA14A filings scheduling annual/special meetings in May 2026, alongside bank M&A momentum (e.g., Flushing Financial/OceanFirst merger approvals at 97%+ support) and insurance positives (MetLife variable income $475-525M Q1 ahead of $1.6B FY guide). Period-over-period trends show mixed results: revenue growth averaging +3-4% YoY in reports like UniFirst (+3.4% Q2, +3.1% H1) and XPO ($8.16B FY25), but frequent margin compression (UniFirst op income -16.7% YoY Q2; CPI Aerostructures gross profit -38.7% YoY) and losses (APEX net loss -371% QoQ). Capital allocation leans toward buybacks (UniFirst $32.7M H1 vs $12.5M prior, up 161%) and debt for M&A (Brink’s $1.225B term loan for NCR Atleos; Four Corners $200M facility). SPAC activity surges with extensions (Legato), new IPOs (RRE Ventures 25M units), and combos (Teamshares/Live Oak Q2 close), while exec changes signal transitions (Mattel CCO promo, Protagenic CFO exit). No widespread insider selling/buying patterns, but MHC stakes (Pioneer 57%) indicate stability. Implications: Near-term catalysts in May meetings/M&A closings favor event-driven trades; deteriorating margins warrant caution in ops-heavy firms.

35 high priority 15 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 07, 2026

Across 49 SEC filings from the USA S&P 500 Consumer Staples intelligence stream (though diverse with proxies, 8-Ks, and 13Fs spanning financials, healthcare, tech, and limited staples like CCEP), proxy season dominates with 15+ DEF 14A/DEFA14A filings scheduling May 2026 AGMs (e.g., Travelers May 20, Xcel May 20, Teladoc May 21), emphasizing governance, say-on-pay, and auditor ratifications amid neutral sentiment. Capital allocation trends positive in select names: CCEP repurchased 290k shares (avg $90+), Ellington declared $0.13 monthly dividend, J.P. Morgan REIT raised $69M via share issuance. Sparse period-over-period data shows resilience (Xcel 6.2% EPS CAGR 2005-2025, 5% dividend CAGR, 23 yrs increases; Teladoc 2025 revenue $2.5B, intl +12% YoY, members +9%), but biotechs flag distress (Cell Source going concern doubt). Leadership transitions smooth (Mattel CCO promo), M&A/divestitures add liquidity (CVD $16.9M SDC sale), SPACs/IPOs active (KPET $200M IPO despite deficit). Portfolio-level: neutral-to-positive sentiment (12 positive, 24 neutral, 4 negative), low YoY trends but May catalysts loom for votes impacting comp/equity plans.

16 high priority 33 medium 49 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 07, 2026

Across 50 SEC filings primarily from diverse sectors misaligned with S&P 500 Industrials (heavy in biotech, finance, hospitality, and proxies), proxy season dominates with 25+ DEF 14A/DEFA14A filings scheduling virtual annual meetings in May 2026, highlighting governance, director elections, and say-on-pay votes amid mixed 2025 performance recaps. Period-over-period trends show revenue resilience (e.g., Collegium + record $780.6M, Tandem ~$1.015B surpassing $1B milestone + significant YoY growth, Global Net Lease AFFO $0.99/share exceeding guidance) but pockets of weakness (Phoenix Education Q2 rev -0.4% YoY, net income -33% YoY; 6-mo net income -58% YoY despite Adj EBITDA +7.4% YoY). Biotech financing surges positively (Opus $155M non-dilutive to extend runway to 2029, Kiora $24M placement), contrasted by Luminar Technologies' confirmed Chapter 11 liquidation (negative for lidar/auto supply chain). Capital allocation leans shareholder-friendly (Phoenix $0.21/share div + $50M buyback, Collegium $25M repurchases + $980M facility, Global Net Lease $2.2B debt reduction), with limited insider activity but strong management voting intent (e.g., Legato insiders for SPAC extension). Forward-looking catalysts cluster in mid-2026 (Opus topline data, INOVIO PDUFA Oct 2026), signaling alpha in turnarounds and M&A amid neutral-to-positive sentiment (18 positive, 24 neutral, 4 negative, 4 mixed). Portfolio-level implication: Favor biotech/healthcare proxies with growth beats and financings over pure industrials voids, watch May proxy outcomes for governance shifts.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 07, 2026

Across the 7 filings in the S&P 500 Energy stream, dominant themes include proxy preparations for 2026 annual meetings at Chevron (CVX) and Cheniere Energy (LNG), with Cheniere highlighting exceptional 2025 results (Net Income >$5.3B, Distributable Cash Flow ~$5.3B, no declines noted). Chevron filings emphasize Hess Corp. acquisition integration (completed July 18, 2025, with John B. Hess joining board), board recommendations FOR directors/auditors/compensation but AGAINST governance proposals, signaling stable leadership amid M&A. Neutral sentiment prevails in Chevron's multiple DEFA14A/DEF 14A (materiality 3-7/10), contrasted by positive tones at Cheniere (8/10) and Stoke Therapeutics (6/10), though non-energy filings like Copper Property (neutral, store disclosures) and Stoke (board addition) dilute sector focus. No explicit YoY/QoQ trends across most, but Cheniere's 'outstanding' 2025 metrics imply strong period-over-period growth; no insider trading, capital allocation, or M&A valuations detailed beyond Hess completion. Key implication: Near-term catalysts from May 2026 AGMs could affirm management conviction, with Cheniere's cash flow supporting returns amid energy transition scrutiny. Portfolio trend: Governance battles highlight ESG risks, but financial strength in LNG (Cheniere) positions energy leaders for upside.

3 high priority 4 medium 7 total filings
· daily

US Material Events SEC 8-K Filings — April 07, 2026

Across 50 filings from April 7, 2026, dominant themes include widespread executive transitions (appointments/resignations in 28 companies, often positive for strategic refresh), a biotech funding surge (e.g., Opus Genetics $155M non-dilutive to 2029 runway, Kiora $24M placement), and liquidity-enhancing maneuvers like sale-leasebacks (New Fortress $266M), asset sales (CVD Equipment $16.9M), and credit facilities (Four Corners $200M term loan). One stark negative: Luminar Technologies Chapter 11 liquidation confirmation signals sector distress in lidar/autonomous tech. Period-over-period data sparse but reveals outliers like Kura Sushi Q2 revenue +23% YoY to $80M, comp sales +8.6%, EBITDA +104% to $5.5M, contrasting Ginkgo Bioworks pro forma 2025 revenue -22% post-Biosecurity divestiture. REIT/industrial financing trends positive with low leverage (Four Corners 5.4x target), while fitness (Xponential strategic review) and tech (WM Technology delisting) show mixed signals amid M&A speculation. Portfolio implication: Favor biotechs with extended runways and monitor leadership churn for conviction shifts.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 07, 2026

The 50 filings for the USA Dow Jones 30 intelligence stream reveal a dominant proxy season theme, with over 25 DEF 14A/DEFA14A filings scheduling virtual annual meetings in mid-May 2026 (e.g., May 19-21), focusing on director elections, auditor ratifications, say-on-pay votes, and plan approvals amid neutral sentiment in most cases. Period-over-period trends show stark contrasts: robust growth in Bread Financial Holdings (net income +87% YoY to $521M, EPS +98% to $10.96), EVERTEC (record 2025 revenue, Latin America expansion), and Global Net Lease (AFFO $0.99/share exceeding guidance, 32% TSR vs peers); offset by collapses like Kaixin Holdings (revenues $31.5M in 2023 to $0 in 2024, losses to $53.9M in 2025) and Phoenix Education (Q2 revenue -0.4% YoY, net income -33% YoY). Capital allocation leans shareholder-friendly with dividends/buybacks (Phoenix $0.21/share div + $50M repurchase; Global Net Lease repurchases amid $2.2B debt cut), while M&A/divestitures provide liquidity (CVD $16.9M SDC sale netting $15M; PROG/P-Squared acquisition). Positive biotech catalysts like Nuvalent's NDA submission contrast liquidity risks (Inotiv covenant waiver). No widespread insider selling/buying patterns, but equity awards signal alignment (Envista CEO 696k shares). Overall, financials/REITs show resilience, biotechs/SPACs offer upside, but select operational distress demands caution.

25 high priority 25 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — April 07, 2026

Across 50 SEC filings for April 7, 2026, dominant themes include a surge in M&A and de-SPAC activity (e.g., Flushing/OceanFirst merger approvals, Talkspace/UHS, Teamshares/Live Oak), proxy statements signaling annual/special meeting season with mixed comp votes, and SPAC/IPO filings amid biotech financings. Period-over-period trends show mixed results: Crane NXT revenue hit 129% of target ($1,568.6M) but op profit at 79%, CPI Aerostructures revenue declined 14.6% YoY to $69.3M with cash plunging 83.6%, and APEX Tech net loss worsened 371% QoQ to $39K. Financial distress evident in Luminar bankruptcy confirmation and Inotiv liquidity waiver, contrasted by positive capital raises like Opus Genetics' $155M funding and Four Corners' $200M loan. Forward-looking catalysts cluster in Q2 2026 (mergers, earnings like MetLife May 6), with biotech runways extended to 2029. Portfolio-level patterns highlight financial sector consolidation (5+ merger votes), neutral sentiment in 13F holdings (stable ETF-heavy portfolios), and bullish de-SPAC momentum implying alpha in transaction completions.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 07, 2026

Across 50 SEC filings from S&P 500 Consumer Discretionary and related sectors, proxy statements dominate (over 25 DEF 14A/DEFA14A) signaling peak annual meeting season in May 2026, with neutral sentiment but emphasis on governance, director elections, and say-on-pay votes. Period-over-period trends show mixed revenue growth (e.g., UniFirst +3.4% YoY Q2, Jefferies +16.1% YoY) offset by widespread margin compression (UniFirst op income -16.7% YoY, CPI Aerostructures gross profit -38.7% YoY) and operational losses (FG Nexus $40-45M Q1 loss, Skillsoft net loss margin -27.3%). Capital allocation leans shareholder-friendly with buybacks (FG Nexus 2.2M shares at $16.04 avg, UniFirst $32.7M H1) and new debt facilities (Four Corners $200M term loan for Q2/Q3 acquisitions). Mergers advance (Flushing/OceanFirst 97.3% approval) amid strategic reviews (Xponential Fitness exploring sale). Bullish highlights include Target Hospitality's $320.6M FY25 revenue/$0 net debt and Bread Financial's 87% YoY net income surge to $521M; risks from Nasdaq non-compliance (Hydrofarm) and auditor changes. Portfolio-level implication: Selective opportunities in resilient retail/hospitality amid margin pressures, monitor May catalysts for governance shifts.

26 high priority 24 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 07, 2026

Across the 50 filings in the USA S&P 500 Healthcare stream (with broader context from financials and biotechs), proxy season dominates with 20+ DEF 14A/DEFA14A filings scheduling May 2026 AGMs, emphasizing governance, director elections, say-on-pay (mixed support at Thermo Fisher), and auditor ratifications. Healthcare-specific trends show resilient large-cap performance (Amgen +10% YoY revenue, record 18 product sales) contrasted by small-cap biotech volatility: positive catalysts like Pulse Biosciences' pivotal trial enrollments and TriSalus CMO promotion, offset by Protagenic CFO exit and NovaBridge's 83% wider operating losses ($94.3M). Capital allocation remains shareholder-friendly with Amgen's $5B dividends/$6B debt reduction, Jackson Financial's 12.5% dividend hike/$1B buyback expansion, and Cintas' $933M repurchases amid 8.9% YoY revenue growth. Merger approvals (Flushing 97.3% yes, OceanFirst issuance approved) signal M&A momentum in adjacents, while Nasdaq compliance regains (Artelo, Tianci) aid biotechs. No major guidance cuts; forward catalysts cluster in May AGMs and clinical milestones (Pulse 6/12-month endpoints). Overall, bullish large-cap stability vs. high-beta biotech risks, with portfolio-level revenue growth averaging +10-16% YoY where reported, but margin pressures in mixed sentiment filings.

25 high priority 25 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — April 07, 2026

Across 50 DEF 14A filings for US companies' 2026 annual meetings (primarily May 19-21), a dominant theme is robust 2025 fiscal performance with 14 companies explicitly reporting YoY revenue growth (avg +28%, range 4%-98%) in sectors like transport/logistics (XPO +LTL EBITDA 4% YoY), airlines (United +7.3% pre-tax margin), pharma (Collegium +48% Jornay PM), and fintech (Bread Financial net income +87% YoY), signaling broad economic resilience despite isolated challenges. Neutral sentiment prevails (32/50), with positive in 12 (e.g., Target Hospitality $0 net debt, Global Net Lease 32% TSR) and mixed in 2; no explicit guidance cuts but forward-looking catalysts include auditor ratifications for FY2026, equity plan expansions (e.g., Mistras +1.7M shares), and PDUFA dates (INOVIO Oct 2026). Capital allocation leans shareholder-friendly with buybacks (Collegium $25M, Rush $193.5M), dividends (Rush +5.6%), and debt reduction (Global Net Lease $2.2B), though dilution risks from incentive plan increases in 5 firms. Portfolio-level trend: 8/14 reporting firms show margin stability/improvement (e.g., XPO LTL +80bps), outperforming peers; sector patterns favor transport/pharma over REITs/funds. Market implication: Buy dips in high-performers pre-May meetings for potential say-on-pay catalysts and TSR boosts.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 07, 2026

The IPO Pipeline stream reveals two high-materiality S-1 filings on April 7, 2026, signaling renewed capital market activity in SPACs and biotech: RRE Ventures Acquisition Corp. launching a 25M-unit IPO and Artelo Biosciences registering 9.8M shares for resale post-$11M private placement. Both exhibit positive sentiment, with Artelo showcasing key turnaround metrics including a 1-for-3 reverse split reducing outstanding shares 65% YoY (2.12M to 736k), full repayment of $665k bridge notes, and Nasdaq compliance regained on April 6 after meeting $2.5M equity threshold. No direct revenue/margin period-over-period trends available due to pre-revenue SPAC and development-stage biotech status, but Artelo's debt reduction and share reduction highlight deleveraging efforts. Cross-filing themes include warrant-heavy structures (RRE: 15.3M warrants at $11.50; Artelo: 6.4M common + 3.1M pre-funded at $3.20), founder/sponsor commitments, and dilution risks, positioning these as speculative plays in a potentially thawing IPO market. Market implications favor tactical positioning ahead of IPO effectiveness and trading launches, with Artelo's compliance as a near-term catalyst.

2 high priority 2 total filings